Literature DB >> 15266615

parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease.

P Poorkaj1, J G Nutt, D James, S Gancher, T D Bird, E Steinbart, G D Schellenberg, Haydeh Payami.   

Abstract

parkin Mutations are the most common identified cause of Parkinson's disease (PD). It has been suggested that patients with young-onset PD be screened for parkin mutations as a part of their clinical work-up. The aim of this study was to assess parkin mutation frequency in a clinical setting, correlate genotype with phenotype, and evaluate the current justification for clinical parkin testing. Patients were selected from a movement disorder clinic based on diagnosis of PD and onset age </=40 years. parkin was genotyped by sequence and dosage analysis for all 12 exons. Key relatives and controls were screened for identified mutations. Mutations were found in 7/39 patients. Two patients were compound heterozygous; five were heterozygous. Mutations included deletions in exons 2, 3, and 8, duplications in exons 2-4, and 9, and P437L substitution. Seventy-eight percent of mutations were deletions/multiplications. A novel substitution (R402W) was found in one patient and in one control. None of the point mutations found in patients were detected in 96 controls. parkin phenotypes were consistent with idiopathic PD. In conclusion, parkin mutations are common in the clinic setting: 10% of PD patients had early-onset and 18% of them had parkin mutations. However, if parkin is recessive, only 5% of early-onset cases who had compound mutations could be attributed to this locus. Mutation frequency was 0.12 (95% CI 0.04-0.19). parkin cases can present as typical idiopathic PD, distinguishable only by molecular testing. Seventy percent of parkin cases were heterozygous. It is unclear whether heterozygous mutations are pathogenic. parkin-based diagnosis and counseling require a better understanding of the mode of inheritance, penetrance, and carrier frequencies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15266615     DOI: 10.1002/ajmg.a.30157

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  14 in total

1.  A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2.

Authors:  D M Kay; C F Stevens; T H Hamza; J S Montimurro; C P Zabetian; S A Factor; A Samii; A Griffith; J W Roberts; E S Molho; D S Higgins; S Gancher; L Moses; S Zareparsi; P Poorkaj; T Bird; J Nutt; G D Schellenberg; H Payami
Journal:  Neurology       Date:  2010-09-28       Impact factor: 9.910

2.  A compendium of human genes regulating feeding behavior and body weight, its functional characterization and identification of GWAS genes involved in brain-specific PPI network.

Authors:  Elena V Ignatieva; Dmitry A Afonnikov; Olga V Saik; Evgeny I Rogaev; Nikolay A Kolchanov
Journal:  BMC Genet       Date:  2016-12-22       Impact factor: 2.797

3.  A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity.

Authors:  Parvoneh Poorkaj; Wendy H Raskind; James B Leverenz; Mark Matsushita; Cyrus P Zabetian; Ali Samii; Sophia Kim; Nayiry Gazi; John G Nutt; John Wolff; Dora Yearout; J Lynne Greenup; Ellen J Steinbart; Thomas D Bird
Journal:  Mov Disord       Date:  2010-07-30       Impact factor: 10.338

4.  Parkin-deficient mice are not a robust model of parkinsonism.

Authors:  Francisco A Perez; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

5.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

6.  Identification and characterization of a novel endogenous murine parkin mutation.

Authors:  Chenere P Ramsey; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

7.  Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease.

Authors:  Carlos A Perez; Yong Tong; Maolin Guo
Journal:  Curr Bioact Compd       Date:  2008-10-01

Review 8.  Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Authors:  Karen Nuytemans; Jessie Theuns; Marc Cruts; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

Review 9.  Parkin-related disease clinically diagnosed as a pallido-pyramidal syndrome.

Authors:  Mindhu M Wickremaratchi; Elisa Majounie; Huw R Morris; Nigel M Williams; Helen Lewis; Steven S Gill; Sadaquate Khan; Peter Heywood; John Hardy; Charles M Wiles; Andrew B Singleton; Niall P Quinn
Journal:  Mov Disord       Date:  2009-01-15       Impact factor: 10.338

10.  Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations.

Authors:  Sarah Teixeira Camargos; Leonardo Oliveira Dornas; Parastoo Momeni; Andrew Lees; John Hardy; Andrew Singleton; Francisco Cardoso
Journal:  Mov Disord       Date:  2009-04-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.